Lattice corneal dystrophy

Summary

Lattice corneal dystrophy (MONDO:0004686) is a disease. A subtype of stromal corneal dystrophy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lattice corneal dystrophy
Mondo ID	MONDO:0004686
DOID	DOID:8943
ICD-10-CM	H18.54
ICD-11	1247885635
SNOMED CT	1192004
UMLS	C0155127
MedGen	56355
GARD	0024087
Is cancer (heuristic)	no

Also known as: lattice corneal dystrophy · lattice corneal dystrophy (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of stromal corneal dystrophy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › corneal disorder › corneal dystrophy › stromal corneal dystrophy › lattice corneal dystrophy

Related subtypes (9): Schnyder corneal dystrophy, fleck corneal dystrophy, granular corneal dystrophy type I, central cloudy dystrophy of François, macular corneal dystrophy, granular corneal dystrophy type II, congenital stromal corneal dystrophy, posterior amorphous corneal dystrophy, pre-descemet corneal dystrophy

Subtypes (3): lattice corneal dystrophy type I, gelatinous drop-like corneal dystrophy, corneal dystrophy, lattice type 3A

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.